Novo Nordisk has suffered another setback in its uphill battle against Eli Lilly in the booming obesity drug market after a US judge rejected its …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
WuXi AppTec raises revenue forecast again in the face of DOD court case October 26, 2026
Beyond the cancer vaccine, how did Merck’s oncology pipeline do at ESMO? October 26, 2026
Lilly’s music-loving, intense lead dealmaker knows what he wants October 26, 2026
Post-Makary FDA wins over investors, but not scientists or Big Pharma: Signal Survey
Artiva to wind down after two patient deaths in autoimmune cell therapy trials
Source link







